{"hands_on_practices": [{"introduction": "Understanding the difference between driver and passenger mutations often begins with inference based on established biological principles. Before launching into complex experiments, a geneticist can form a strong hypothesis by combining knowledge of a gene's known function with the predictable outcome of a specific mutation type. This first practice challenges you to do just that: by analyzing a nonsense mutation within a known tumor suppressor gene, you can deduce its likely role in cancer progression without needing a functional assay [@problem_id:1485130].", "problem": "A team of cancer biologists is studying a tumor biopsy from a patient. Through genomic sequencing of the cancer cells, they identify a mutation in a gene they have named `CGR1` (Cell Growth Regulator 1). Previous large-scale functional genomic studies have firmly established that the protein product of the `CGR1` gene acts as a tumor suppressor by pausing the cell cycle in response to Deoxyribonucleic Acid (DNA) damage. The specific mutation identified is a single nucleotide substitution that changes a codon for the amino acid Tryptophan into a stop codon. This change occurs early in the gene's coding sequence, leading to the production of a severely truncated protein.\n\nBased on the provided biological context, which of the following statements most accurately classifies this specific mutation in the `CGR1` gene and provides the correct reasoning?\n\nA. This is likely a passenger mutation, as single nucleotide changes are minor and rarely have a significant functional impact on the resulting protein.\n\nB. This is likely a driver mutation because a nonsense mutation in a tumor suppressor gene constitutes a gain-of-function that actively promotes uncontrolled cell division.\n\nC. This is likely a passenger mutation because the vast majority of mutations found within a tumor's genome do not confer any selective growth advantage and are biochemically neutral.\n\nD. This is likely a driver mutation because a nonsense mutation in a tumor suppressor gene results in a loss of its normal function, providing a selective growth advantage to the cell.\n\nE. It is impossible to classify this mutation as either a driver or a passenger without first confirming through sequencing that the second allele of the `CGR1` gene is also inactivated.", "solution": "We are told that `CGR1` encodes a protein that functions as a tumor suppressor by pausing the cell cycle in response to DNA damage. The identified mutation is a single nucleotide substitution that converts a Tryptophan codon into a stop codon early in the coding sequence, i.e., a premature termination codon (a nonsense mutation), producing a severely truncated protein.\n\nFirst, define the relevant biological categories. A driver mutation is one that confers a selective growth advantage to the cell, causally contributing to oncogenesis. A passenger mutation is one that does not contribute to tumor development and is biologically neutral with respect to cellular fitness in the tumor context. Tumor suppressor genes normally act as brakes on cell proliferation or maintain genomic integrity; their loss-of-function promotes tumorigenesis. Oncogenes, by contrast, typically drive cancer via gain-of-function alterations.\n\nNext, evaluate the functional impact of the specific mutation type and context. A nonsense mutation early in the coding region typically causes either nonsense-mediated mRNA decay or production of a truncated protein that lacks essential domains, both of which are strong forms of loss-of-function. In the context of a tumor suppressor that enforces a DNA damage checkpoint, such loss-of-function removes a critical brake on proliferation and permits propagation despite DNA damage, which confers a selective growth advantage—meeting the definition of a driver.\n\nNow assess each option in light of these principles:\n- Option A is incorrect: single nucleotide substitutions can have major functional consequences; a premature stop codon early in the coding sequence is a classic strong loss-of-function mutation and is not “minor.”\n- Option B is incorrect: the effect described is not a gain-of-function; nonsense mutations cause loss-of-function, and gain-of-function is characteristic of oncogenes, not tumor suppressors.\n- Option C is overly generic and incorrect for this specific case: while many tumor mutations are passengers, a truncating nonsense mutation in a known tumor suppressor with a critical checkpoint role is unlikely to be neutral and is instead likely to be a driver.\n- Option D is correct: a nonsense mutation in a tumor suppressor gene produces loss of normal function, removing growth control and providing a selective advantage, i.e., a driver mutation.\n- Option E is misleading: although many tumor suppressors follow a two-hit pattern, classification of this specific mutation as a driver does not require prior confirmation of second allele inactivation; truncating mutations in established tumor suppressors are canonical driver-type events, and haploinsufficiency or additional mechanisms (e.g., loss of heterozygosity, dominant-negative effects, or later second hits) often occur. The question asks for the most accurate classification and reasoning for this specific mutation type in context, which aligns with a driver due to loss-of-function.\n\nTherefore, the most accurate choice is that this is likely a driver mutation because a nonsense mutation in a tumor suppressor gene results in loss of its normal function, providing a selective growth advantage.", "answer": "$$\\boxed{D}$$", "id": "1485130"}, {"introduction": "While logical inference is a powerful tool, the gold standard in science is experimental proof. To definitively classify a mutation as a driver, one must demonstrate that it can *cause* cancerous traits. This exercise explores the design and interpretation of such a functional assay, where modern gene-editing technology is used to introduce a candidate mutation into healthy cells to see if it confers a cancerous phenotype [@problem_id:1485160].", "problem": "In the field of cancer genetics, mutations found in tumor cells are broadly categorized as either \"driver\" or \"passenger\" mutations. A research team is investigating the genetic landscape of a malignant melanoma. They sequence the entire exome of the tumor cells and identify a novel point mutation in a gene they designate `SKP3`. To determine the functional significance of this mutation, they use Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9 gene-editing technology to introduce this exact `SKP3` mutation into a line of healthy, non-cancerous human melanocytes (pigment-producing cells). They observe that the engineered melanocytes begin to proliferate rapidly and lose their normal property of contact inhibition, continuing to divide even after forming a confluent monolayer in the culture dish.\n\nBased on this experimental result, which of the following statements provides the most accurate conclusion about the nature of the `SKP3` mutation?\n\nA. The `SKP3` mutation is a passenger mutation because it was identified from a sequenced tumor.\n\nB. The `SKP3` mutation is a driver mutation because it confers a phenotype associated with cancerous growth.\n\nC. The `SKP3` experiment is inconclusive, as the mutation's effect could be an artifact of the cell culture environment.\n\nD. The `SKP3` mutation is a germline mutation, meaning it was inherited by the patient.\n\nE. The gene `SKP3` must be a tumor suppressor gene.", "solution": "- Define terms: A driver mutation is one that causally contributes to oncogenesis by conferring a growth or survival advantage, leading to positive selection in the tumor cell population. A passenger mutation is biologically neutral with respect to tumorigenesis and accumulates without contributing to cancer phenotypes.\n- Interpret the experiment: The researchers used CRISPR-Cas9 to introduce the exact tumor-identified point mutation in the gene designated `SKP3` into otherwise healthy human melanocytes. Following introduction of this single mutation, the cells exhibited rapid proliferation and loss of contact inhibition, both hallmark phenotypes associated with oncogenic transformation.\n- Causal inference: Because the only engineered change is the precise `SKP3` point mutation, and this change is sufficient to induce cancer-associated phenotypes in non-cancerous cells, the mutation has a demonstrated causal effect on promoting oncogenic behavior. This satisfies the definition of a driver mutation.\n- Evaluate alternatives:\n  - Option A is incorrect: Being found in a tumor does not define a mutation as a passenger; functional assays demonstrating growth advantage contradict the passenger designation.\n  - Option C is not the most accurate: While experimental artifacts are always a consideration, the direct genotype-to-phenotype result with CRISPR-mediated introduction of the specific mutation supports causality; standard practice would include appropriate controls, but given the observed robust transformation-associated phenotypes, the most accurate conclusion is that it is a driver.\n  - Option D is incorrect: The observation pertains to a somatic mutation identified in a tumor and functionally tested in vitro; no evidence is provided to classify it as germline.\n  - Option E is incorrect: The data do not establish that `SKP3` must be a tumor suppressor. A single point mutation that is sufficient to induce hyperproliferation and loss of contact inhibition is more consistent with a gain-of-function (oncogenic) effect, not necessarily loss of function in a tumor suppressor. Therefore, no such categorical conclusion can be made.\n- Conclusion: The functional assay demonstrates that the `SKP3` mutation drives cancer-associated phenotypes; therefore, it is a driver mutation.", "answer": "$$\\boxed{B}$$", "id": "1485160"}, {"introduction": "Once a gene is confirmed as a driver, a new set of questions emerges: Is this driver important for all cancers, or only for specific types? This phenomenon, known as \"lineage-specific oncogene addiction,\" is a critical concept for developing targeted therapies. This final practice puts you in the role of a data analyst, asking you to process raw experimental data from a CRISPR screen to quantify a driver gene's importance across different cancer cell lines and test a hypothesis about its selectivity [@problem_id:1485120].", "problem": "A cancer biologist has identified a gene, designated `GENE-Z`, which is frequently mutated in colorectal cancer. The hypothesis is that this mutation is a \"lineage-specific\" driver, meaning that colorectal cancer cells become highly dependent on the activity of this gene for their survival and proliferation, a phenomenon known as oncogene addiction. To test this hypothesis, a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9 knockout experiment was performed on a panel of cancer cell lines.\n\nThe experiment involves transducing cells with a lentivirus carrying the Cas9 nuclease and a guide Ribonucleic Acid (gRNA) targeting an essential exon of `GENE-Z`. As a control, a parallel set of cells for each line was transduced with a lentivirus containing a non-targeting gRNA. After 7 days, cell viability was measured, and the results for the `GENE-Z` knockout group were normalized to the control group, yielding a \"Relative Viability\" score.\n\nThe experimental data for seven different cell lines are provided below:\n\n| Cell Line ID | Cancer Type | Relative Viability |\n|--------------|-------------|--------------------|\n|   CL-01      | Colon       | 0.25               |\n|   CL-02      | Colon       | 0.19               |\n|   CL-03      | Colon       | 0.31               |\n|   LU-01      | Lung        | 0.92               |\n|   LU-02      | Lung        | 0.88               |\n|   BR-01      | Breast      | 0.95               |\n|   BR-02      | Breast      | 0.91               |\n\nTo quantify the dependency of each cell line on `GENE-Z`, a \"Dependency Score\" ($DS$) is defined as:\n$$DS = 1 - (\\text{Relative Viability})$$\n\nA higher $DS$ indicates a stronger dependency. To evaluate the lineage-specificity of this dependency, you are asked to calculate a \"Colon-Selectivity Index\" ($CSI$). This index is defined as the ratio of the average Dependency Score of the colon cancer cell lines to the average Dependency Score of all non-colon (i.e., lung and breast) cancer cell lines in the panel.\n\nCalculate the Colon-Selectivity Index ($CSI$) based on the provided data. Round your final answer to three significant figures.", "solution": "We are given the definition of the Dependency Score as $DS = 1 - (\\text{Relative Viability})$. For each cell line, compute $DS$.\n\nFor colon cancer cell lines:\n$$DS_{\\text{CL-01}} = 1 - 0.25 = 0.75,$$\n$$DS_{\\text{CL-02}} = 1 - 0.19 = 0.81,$$\n$$DS_{\\text{CL-03}} = 1 - 0.31 = 0.69.$$\n\nCompute the average Dependency Score for colon lines:\n$$\\overline{DS}_{\\text{colon}} = \\frac{0.75 + 0.81 + 0.69}{3} = \\frac{2.25}{3} = 0.75.$$\n\nFor non-colon cancer cell lines (lung and breast):\n$$DS_{\\text{LU-01}} = 1 - 0.92 = 0.08,$$\n$$DS_{\\text{LU-02}} = 1 - 0.88 = 0.12,$$\n$$DS_{\\text{BR-01}} = 1 - 0.95 = 0.05,$$\n$$DS_{\\text{BR-02}} = 1 - 0.91 = 0.09.$$\n\nCompute the average Dependency Score for non-colon lines:\n$$\\overline{DS}_{\\text{non-colon}} = \\frac{0.08 + 0.12 + 0.05 + 0.09}{4} = \\frac{0.34}{4} = 0.085.$$\n\nThe Colon-Selectivity Index is defined as the ratio of these averages:\n$$CSI = \\frac{\\overline{DS}_{\\text{colon}}}{\\overline{DS}_{\\text{non-colon}}} = \\frac{0.75}{0.085} = \\frac{150}{17} \\approx 8.823529\\ldots.$$\n\nRounding to three significant figures gives:\n$$CSI \\approx 8.82.$$", "answer": "$$\\boxed{8.82}$$", "id": "1485120"}]}